Ganciclovir implant in the treatment of cytomegalovirus retinitis

Margaret Chang, James P. Dunn

Research output: Contribution to journalReview articlepeer-review

18 Scopus citations


The ganciclovir implant is a sustained-release intraocular drug delivery system used to treat cytomegalovirus retinitis that provides a high and steady-state concentration of the drug in the vitreous cavity over a period of 7-8 months. Randomized, controlled clinical trials have demonstrated a superior efficacy of the implant compared with intravenous ganciclovir. Severe adverse events associated with the implant are uncommon, though potentially blinding. In addition, the implant provides no protection against second-eye or visceral cytomegalovirus retinitis infections. This review summarizes the clinical indications for and complications associated with the ganciclovir implant.

Original languageEnglish (US)
Pages (from-to)421-427
Number of pages7
JournalExpert review of medical devices
Issue number4
StatePublished - Jul 2005


  • Cidofovir
  • Cytomegalovirus DNA polymerase
  • Cytomegalovirus retinitis
  • Endophthalmitis
  • Foscarnet
  • Ganciclovir
  • Ganciclovir implant
  • Retinal detachment
  • Viral resistance

ASJC Scopus subject areas

  • Surgery
  • Biomedical Engineering


Dive into the research topics of 'Ganciclovir implant in the treatment of cytomegalovirus retinitis'. Together they form a unique fingerprint.

Cite this